Literature DB >> 24333005

Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder.

Maju Mathew Koola1, David A Gorelick2, Robert P McMahon3, Fang Liu3, Marilyn A Huestis4, Jared Linthicum3, Stephanie M Feldman3, Kimberly R Warren5, Heidi J Wehring3, Deanna L Kelly3.   

Abstract

Entities:  

Keywords:  Alcohol; Cannabis; Lifetime substance use; Schizophrenia; Symptoms

Mesh：

Year:  2013        PMID： 24333005      PMCID： PMC4543288          DOI： 10.1016/j.schres.2013.11.035

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  6 in total

1.  Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Authors:  Douglas L Boggs; Deanna L Kelly; Robert P McMahon; James M Gold; David A Gorelick; Jared Linthicum; Robert R Conley; Fang Liu; James Waltz; Marilyn A Huestis; Robert W Buchanan
Journal:  Schizophr Res       Date:  2011-12-03       Impact factor: 4.939

2.  Reliability and validity of a depression rating scale for schizophrenics.

Authors:  D Addington; J Addington; E Maticka-Tyndale; J Joyce
Journal:  Schizophr Res       Date:  1992-03       Impact factor: 4.939

3.  Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.

Authors:  Julie Kreyenbuhl; Eric P Slade; Deborah R Medoff; Clayton H Brown; Benjamin Ehrenreich; Joseph Afful; Lisa B Dixon
Journal:  Schizophr Res       Date:  2011-05-14       Impact factor: 4.939

4.  Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.

Authors:  Deanna L Kelly; David A Gorelick; Robert R Conley; Douglas L Boggs; Jared Linthicum; Fang Liu; Stephanie Feldman; M Patricia Ball; Heidi J Wehring; Robert P McMahon; Marilyn A Huestis; Stephen J Heishman; Kimberly R Warren; Robert W Buchanan
Journal:  J Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.153

Review 5.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

6.  An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index.

Authors:  A T McLellan; L Luborsky; G E Woody; C P O'Brien
Journal:  J Nerv Ment Dis       Date:  1980-01       Impact factor: 2.254
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.